EAM Investors’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-380,691
Closed -$3.13M 377
2022
Q3
$3.13M Buy
380,691
+194,489
+104% +$1.49M 0.68% 25
2022
Q2
$1.22M Buy
+186,202
New +$902K 0.3% 155
2018
Q2
Sell
-37,764
Closed -$1.09M 393
2018
Q1
$1.09M Sell
37,764
-409
-1% -$12K 0.18% 193
2017
Q4
$1.06M Sell
38,173
-40,361
-51% -$1.25M 0.19% 190
2017
Q3
$2.87M Sell
78,534
-10,629
-12% -$329K 0.38% 76
2017
Q2
$1.98M Buy
+89,163
New +$702K 0.33% 155

Other funds holding AVEO

EAM Investors's AVEO Position: Q4 2022 in Review

EAM Investors sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q4 2022, closing a stake of 380,691 shares — an estimated $3.13M sold.

EAM Investors first reported a position in AVEO in Q2 2017 and held it in 6 quarters. The position peaked at $3.13M in Q3 2022. 110 funds tracked by Wall St. Rank hold AVEO as of Q4 2022.

  • EAM Investors reported no remaining AVEO Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • EAM Investors sold 380,691 AVEO Pharmaceuticals, Inc. shares in Q4 2022, an estimated $3.13M.
  • EAM Investors first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2017 and held it in 6 quarters.
  • EAM Investors's AVEO Pharmaceuticals, Inc. position peaked at $3.13M in Q3 2022.
  • 110 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q4 2022.

Based on EAM Investors's 13F filing for Q4 2022, filed 14 Feb 2023.